21-Apr-2026
No headlines found.
Globe Newswire (Mon, 13-Apr 9:15 AM ET)
PolyPid Initiates D-PLEX100 NDA Submission to the FDA
Globe Newswire (Tue, 31-Mar 8:30 AM ET)
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX100's New Drug Application
Globe Newswire (Tue, 17-Mar 8:30 AM ET)
PolyPid Announces Participation in Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 8:35 AM ET)
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Globe Newswire (Wed, 11-Feb 7:30 AM ET)
Globe Newswire (Wed, 28-Jan 8:00 AM ET)
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Polypid Ltd. - trades on the NASDAQ stock market under the symbol PYPD.
As of April 21, 2026, PYPD stock price declined to $4.54 with 36,712 million shares trading.
PYPD has a beta of 0.89, meaning it tends to be less sensitive to market movements. PYPD has a correlation of 0.10 to the broad based SPY ETF.
PYPD has a market cap of $46.27 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PYPD traded as high as $13.50 and as low as $2.30.
PYPD has outperformed the market in the last year with a price return of +65.1% while the SPY ETF gained +38.4%. However, in the short term, PYPD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.1% vs +3.0% return in SPY. But in the last 2 weeks, PYPD shares have fared better than the market returning +10.2% compared to SPY +6.8%.
PYPD support price is $4.52 and resistance is $4.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYPD shares will trade within this expected range on the day.